{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-032552","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.134432+00:00","generated_at":"2026-06-20T23:12:28.742547+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sangamo Therapeutics expands ATM equity offering capacity by $175M to $325M total","bullets":["Amendment No. 2 with Jefferies LLC adds $175M in common stock to existing at-the-market program.","Prior to amendment, $115M of original $150M capacity had been sold.","Remaining capacity under amended agreement is approximately $210M (based on $325M total less $115M sold).","Terms and conditions of the Sales Agreement unchanged; shares sold at market prices under effective shelf registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-032552","json":"https://secwatch.observer/filing/0001628280-22-032552.json","markdown":"https://secwatch.observer/filing/0001628280-22-032552.md","text":"https://secwatch.observer/filing/0001628280-22-032552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022032552/0001628280-22-032552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022032552/sgmo-20221223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:12:28.742547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"356c512a6fd07bcf605550949b8c321106fc3777","claim":"SANGAMO THERAPEUTICS, INC amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $175 million (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement (\"Amendment No. 2\" and, together with the Sales Agreement, the \"Amended Sales Agreement\") to provide for an increase in the aggregate offering amount under the Sales Agreement such that the Company may offer and sell additional shares of Common Stock having an aggregate offering amount of up to $175 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022032552/0001628280-22-032552-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $175 million"},{"label":"Effective","value":"2022-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}